807 related articles for article (PubMed ID: 19464103)
1. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
3. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
4. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
5. Distinct regulation of insulin receptor substrate-1 and -2 by 90-kDa heat-shock protein in adrenal chromaffin cells.
Yoshikawa N; Nemoto T; Satoh S; Maruta T; Yanagita T; Chosa E; Wada A
Neurochem Int; 2010 Jan; 56(1):42-50. PubMed ID: 19737590
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
[TBL] [Abstract][Full Text] [Related]
7. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
9. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
[TBL] [Abstract][Full Text] [Related]
10. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
11. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor].
Yu WJ; Rao Q; Wang M; Tian Z; Xu ZF; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):677-80. PubMed ID: 18399173
[TBL] [Abstract][Full Text] [Related]
12. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
13. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
Jayanthan A; Fowler J; Hawkins L; Lamers F; Teja B; Incoronato A; Anderson R; Narendran A
J Exp Ther Oncol; 2008; 7(3):183-93. PubMed ID: 19066127
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
15. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
16. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS
J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756
[TBL] [Abstract][Full Text] [Related]
19. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL
J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348
[TBL] [Abstract][Full Text] [Related]
20. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]